Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib | Zendy

Ali Jabbari | Zendy; Zhenpeng Dai | Zendy; Luzhou Xing | Zendy; Jane Cerise | Zendy; Yuval Ramot | Zendy; Yackov Berkun | Zendy; Gina A. Montealegre Sanchez | Zendy; Raphaela GoldbachMansky | Zendy; Angela M. Christiano | Zendy; Raphael Clynes | Zendy; Abraham Zlotogorski | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib

Author(s) -

Ali Jabbari,

Zhenpeng Dai,

Luzhou Xing,

Jane Cerise,

Yuval Ramot,

Yackov Berkun,

Gina A. Montealegre Sanchez,

Raphaela GoldbachMansky,

Angela M. Christiano,

Raphael Clynes,

Abraham Zlotogorski

Publication year - 2015

Publication title -

ebiomedicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.596

H-Index - 63

ISSN - 2352-3964

DOI - 10.1016/j.ebiom.2015.02.015

Subject(s) - medicine , alopecia areata , concomitant , in vivo , hair loss , clinical trial , dermatology , microbiology and biotechnology , biology

Alopecia areata (AA) is an autoimmune disease resulting in hair loss with devastating psychosocial consequences. Despite its high prevalence, there are no FDA-approved treatments for AA. Prior studies have identified a prominent interferon signature in AA, which signals through JAK molecules.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research